University of Thessaly (UTH)
Επίδραση της φαρμακευτικής αγωγής στη μεσοτοιχωματική κλασματική βράχυνση σε ασθενείς με αρτηριακή υπέρταση
Abstract
dc:descriptionThe present study was designed to assess the effect of two novel drugs, nebivolol, a highly selective beta 1 adrenoreceptor blocking agent with peripheral vasodilating properties, and telmisartan, a highly selective antagonist of type 1 angiotensin II receptors on arterial blood pressure (BP) and left ventricular (LV) structure and performance in untreated patients with essential hypertension. 40 patients with mild to moderate hypertension were randomized to receive either nebivolol (2,5 – 5,0 mg/d) or telmisartan (40 – 80 mg/d) to achieve a target diastolic BP of < 90 mmHg, and 19 healthy volunteers served as controls. BP was measured with sphygmomanometry, whereas LV mass and midwall fractional shortening (mFS) were estimated by 2D-guided M-mode echocardiography and LV diastolic filling was evaluated by Doppler echocardiography at baseline and at the three-month follow-up. Age, sex distribution, and baseline heart rate, body mass index and systolic and diastolic BP were similar in the two drug groups. Both nebivolol and telmisartan reduced systolic (156 ± 7 vs 124 ± 8 mmHg, p<0,01 and 153 ± 5 vs 120 ± 7 mmHg, p< 0,01, respectively) and diastolic BP (99 ± 4 vs 80 ± 2 mmHg, p<0,01 and 98 ± 2 vs 80 ±2 mmHg, p<0,01, respectively) and increased mFS (16 ± 2% vs 19 ± 2%, p<0,01 and 15 ± 2% vs 18 ± 2%, p<0,01, respectively). LV mass index decreased significantly with both nebivolol (98 ± 16 vs 84 ± 13 g/m2, p<0,01) and telmisartan (97 ± 13 vs 83 ± 8 g/m2, p<0,01). mFS was inversely related to diastolic blood pressure in the nebivolol but not in the telmisartan group. The findings of the present study indicate that abnormalities of midwall mechanics parallel those of transmitral diastolic flow in untreated patients with mild to moderate essential hypertension and normal LV ejection fraction. The disparity between midwall and endocardial mechanics confirms the need to measure mFS to track the beneficial effect of antihypertensive treatment. Nebivolol and telmisartan are equally effective in decreasing systolic and diastolic blood pressure and in increasing mFS. There may be differences between nebivolol and telmisartan regarding the mechanism of increase in mFS.
Degree
thesis:*- Grantor dc:publisher
- University of Thessaly (UTH)
- Year dc:date
- 2005
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Fountoulaki, Ekaterini
- Φουντουλάκη, Αικατερίνη
Subjects
dc:subject × 12Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/33972